An epidermal growth factor receptor compound mutation of L858R with S768I in advanced non-small-cell lung cancer: a case report.
EGFR mutation
Afatinib
Case report
L858R
S768I
Journal
Journal of medical case reports
ISSN: 1752-1947
Titre abrégé: J Med Case Rep
Pays: England
ID NLM: 101293382
Informations de publication
Date de publication:
18 Mar 2024
18 Mar 2024
Historique:
received:
11
12
2023
accepted:
30
01
2024
medline:
18
3
2024
pubmed:
18
3
2024
entrez:
18
3
2024
Statut:
epublish
Résumé
In the current treatment landscape for non-small cell lung cancers, epidermal growth factor receptor-tyrosine kinase inhibitors have emerged as a well-established treatment option for patients with advanced or metastatic disease. This is particularly true for those with commonly occurring epidermal growth factor receptor mutations. However, the therapeutic efficacy of these agents for so-called rare epidermal growth factor receptor mutations, and in particular those characterized by a high degree of complexity, such as double mutations, remains a subject of clinical uncertainty. In this context, we present the case of a 64-year-old man of Moroccan descent, a lifelong non-smoker, diagnosed with metastatic non-small cell lung cancer characterized by a complex epidermal growth factor receptor mutation encompassing L858R and S768I. The patient subsequently underwent afatinib-based treatment, showing notable clinical results. These included a remarkable overall survival of 51 months, with a median progression-free survival of more than 39 months. This case report is a compelling testimony to the evolving therapeutic landscape of non-small cell lung cancers, providing valuable insight into the potential therapeutic efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in the realm of rare and complex epidermal growth factor receptor mutations.
Sections du résumé
BACKGROUND
BACKGROUND
In the current treatment landscape for non-small cell lung cancers, epidermal growth factor receptor-tyrosine kinase inhibitors have emerged as a well-established treatment option for patients with advanced or metastatic disease. This is particularly true for those with commonly occurring epidermal growth factor receptor mutations. However, the therapeutic efficacy of these agents for so-called rare epidermal growth factor receptor mutations, and in particular those characterized by a high degree of complexity, such as double mutations, remains a subject of clinical uncertainty.
CASE PRESENTATION
METHODS
In this context, we present the case of a 64-year-old man of Moroccan descent, a lifelong non-smoker, diagnosed with metastatic non-small cell lung cancer characterized by a complex epidermal growth factor receptor mutation encompassing L858R and S768I. The patient subsequently underwent afatinib-based treatment, showing notable clinical results. These included a remarkable overall survival of 51 months, with a median progression-free survival of more than 39 months.
CONCLUSIONS
CONCLUSIONS
This case report is a compelling testimony to the evolving therapeutic landscape of non-small cell lung cancers, providing valuable insight into the potential therapeutic efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in the realm of rare and complex epidermal growth factor receptor mutations.
Identifiants
pubmed: 38494473
doi: 10.1186/s13256-024-04422-5
pii: 10.1186/s13256-024-04422-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
118Informations de copyright
© 2024. The Author(s).
Références
D’Addario G, Früh M, Reck M, Baumann P, Klepetko W, Felip E. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment, and followup. Ann Oncol. 2010;21(Suppl. 5):116–9. https://doi.org/10.1093/annonc/mdq189 .
doi: 10.1093/annonc/mdq189
Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542–50. https://doi.org/10.1056/NEJMoa061884 .
doi: 10.1056/NEJMoa061884
pubmed: 17167137
Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129-2139. doi:10.1056/NEJMOA040938
Witta SE, Jotte RM, Konduri K, et al. Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy. J Clin Oncol. 2012;30(18):2248–55. https://doi.org/10.1200/JCO.2011.38.9411 .
doi: 10.1200/JCO.2011.38.9411
pubmed: 22508830
pmcid: 4798782
Keam B, Kim DW, Park JH, et al. Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer. Int J Clin Oncol. 2014;19(4):594–600. https://doi.org/10.1007/S10147-013-0602-1 .
doi: 10.1007/S10147-013-0602-1
pubmed: 23912954
Kauffmann-Guerrero D, Huber RM, Reu S, et al. NSCLC patients harbouring rare or complex EGFR mutations are more often smokers and might not benefit from first-line tyrosine kinase inhibitor therapy. Respiration. 2018;95(3):169–76. https://doi.org/10.1159/000484175 .
doi: 10.1159/000484175
pubmed: 29190621
Tam IYS, Leung ELH, Tin VPC, et al. Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations. Mol Cancer Ther. 2009;8(8):2142–51. https://doi.org/10.1158/1535-7163.MCT-08-1219 .
doi: 10.1158/1535-7163.MCT-08-1219
pubmed: 19671738
Kobayashi S, Canepa HM, Bailey AS, et al. Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors. J Thorac Oncol. 2013;8(1):118–22. https://doi.org/10.1097/JTO.0B013E3182781E35 .
doi: 10.1097/JTO.0B013E3182781E35
Young Kim E, Na Cho E, Surng Park H, et al. Compound EGFR mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma. Cancer Biol Ther. 2016;17:237. https://doi.org/10.1080/15384047.2016.1139235 .
doi: 10.1080/15384047.2016.1139235
Hata A, Yoshioka H, Fujita S, et al. Complex mutations in the epidermal growth factor receptor gene in non-small cell lung cancer. J Thorac Oncol. 2010;5(10):1524–8. https://doi.org/10.1097/JTO.0B013E3181E8B3C5 .
doi: 10.1097/JTO.0B013E3181E8B3C5
pubmed: 20808254
Zhao W, Song A, Xu Y, et al. Rare mutation-dominant compound EGFR-positive NSCLC is associated with enriched kinase domain-resided variants of uncertain significance and poor clinical outcomes. BMC Med. 2023;21(1):1–16. https://doi.org/10.1186/S12916-023-02768-Z/FIGURES/5 .
doi: 10.1186/S12916-023-02768-Z/FIGURES/5
Kitadai R, Okuma Y. Treatment strategies for non-small cell lung cancer harboring common and uncommon EGFR mutations: drug sensitivity based on exon classification, and structure-function analysis. Cancers (Basel). 2022;14(10):2519. https://doi.org/10.3390/CANCERS14102519 .
doi: 10.3390/CANCERS14102519
pubmed: 35626123
pmcid: 9139782
Wu SG, Yu CJ, Yang JCH, Shih JY. The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation. Ther Adv Med Oncol. 2020;12:1758835920946156. https://doi.org/10.1177/1758835920946156 .
doi: 10.1177/1758835920946156
pubmed: 32843903
pmcid: 7418472
Bethune G, Bethune D, Ridgway N, Xu Z. Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. J Thorac Dis. 2010;2(1):48. https://doi.org/10.3978/J.ISSN.2072-1439.2010.02.01.017 .
doi: 10.3978/J.ISSN.2072-1439.2010.02.01.017
pubmed: 22263017
pmcid: 3256436
Gupta R, Dastane AM, Forozan F, et al. Evaluation of EGFR abnormalities in patients with pulmonary adenocarcinoma: the need to test neoplasms with more than one method. Mod Pathol. 2009;22(1):128–33. https://doi.org/10.1038/modpathol.2008.182 .
doi: 10.1038/modpathol.2008.182
pubmed: 18997733
Yasuda H, Park E, Yun CH, et al. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med. 2013;5:216. https://doi.org/10.1126/SCITRANSLMED.3007205/SUPPL_FILE/5-216RA177_SM.PDF .
doi: 10.1126/SCITRANSLMED.3007205/SUPPL_FILE/5-216RA177_SM.PDF
Leventakos K, Kipp BR, Rumilla KM, Winters JL, Yi ES, Mansfield AS. Brief report: S768I mutation in EGFR in patients with lungcancer. J Thorac Oncol. 2016;11(10):1798. https://doi.org/10.1016/J.JTHO.2016.05.007 .
doi: 10.1016/J.JTHO.2016.05.007
pubmed: 27211795
pmcid: 5035584
Yang JCH, Sequist LV, Geater SL, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015;16(7):830–8. https://doi.org/10.1016/S1470-2045(15)00026-1 .
doi: 10.1016/S1470-2045(15)00026-1
pubmed: 26051236
Zhu X, Bai Q, Lu Y, et al. Response to tyrosine kinase inhibitors in lung adenocarcinoma with the rare epidermal growth factor receptor mutation S768I: a retrospective analysis and literature review. Target Oncol. 2017;12(1):81–8. https://doi.org/10.1007/s11523-016-0455-4 .
doi: 10.1007/s11523-016-0455-4
pubmed: 27538584
Kohsaka S, Petronczki M, Solca F, Maemondo M. Tumor clonality and resistance mechanisms in EGFR mutation-positive non-small-cell lung cancer: Implications for therapeutic sequencing. Futur Oncol. 2019;15(6):637–52. https://doi.org/10.2217/fon-2018-0736 .
doi: 10.2217/fon-2018-0736
Peng L, Song Z, Jiao S. Comparison of uncommon EGFR exon 21 L858R compound mutations with single mutation. Onco Targets Ther. 2015;8:905–10. https://doi.org/10.2147/OTT.S78984 .
doi: 10.2147/OTT.S78984
pubmed: 25960661
pmcid: 4410901
Li M, Zhou CZ, Yang JJ, et al. The in cis compound EGFR mutations in Chinese advanced non-small cell lung cancer patients. Cancer Biol Ther. 2019;20(8):1097–104. https://doi.org/10.1080/15384047.2019.1595280/SUPPL_FILE/KCBT_A_1595280_SM0961.PPTX .
doi: 10.1080/15384047.2019.1595280/SUPPL_FILE/KCBT_A_1595280_SM0961.PPTX
pubmed: 30990107
pmcid: 6605978
Kobayashi S, Canepa HM, Bailey AS, et al. Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors. J Thorac Oncol. 2013;8(1):118–22. https://doi.org/10.1097/JTO.0B013E3182781E35 .
doi: 10.1097/JTO.0B013E3182781E35
Kim EY, Cho EN, Park HS, et al. Compound EGFR mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma. Cancer Biol Thera. 2016;17(3):237–45. https://doi.org/10.1080/15384047.2016.1139235 .
doi: 10.1080/15384047.2016.1139235
Xu H, Yang G, Liu R, et al. EGFR uncommon alterations in advanced non-small cell lung cancer and structural insights into sensitivity to diverse tyrosine kinase inhibitors. Front Pharmacol. 2022;13:3791. https://doi.org/10.3389/FPHAR.2022.976731/BIBTEX .
doi: 10.3389/FPHAR.2022.976731/BIBTEX
Chen K, Yu X, Wang H, et al. Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients. Cancer Chemother Pharmacol. 2017;80(6):1179–87. https://doi.org/10.1007/S00280-017-3464-9 .
doi: 10.1007/S00280-017-3464-9
pubmed: 29063948
Cho JH, Lim SH, An HJ, et al. Osimertinib for patients with non-small-cell lung cancer harboring uncommon EGFR mutations: a multicenter, open-label, phase II trial (KCSG-Lu15-09). J Clin Oncol. 2020;38(5):488–95. https://doi.org/10.1200/JCO.19.00931 .
doi: 10.1200/JCO.19.00931
pubmed: 31825714
Masuda T, Sunaga N, Kasahara N, et al. Successful afatinib rechallenge in a patient with non-small cell lung cancer harboring EGFR G719C and S768I mutations. Thorac cancer. 2020;11(8):2351–6. https://doi.org/10.1111/1759-7714.13532 .
doi: 10.1111/1759-7714.13532
pubmed: 32529804
pmcid: 7396375
Huang CH, Ju JS, Chiu TH, et al. Afatinib treatment in a large real-world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation. Int J cancer. 2022;150(4):626–35. https://doi.org/10.1002/IJC.33821 .
doi: 10.1002/IJC.33821
pubmed: 34558665
Eide IJZ, Stensgaard S, Helland Å, et al. Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations: a post-hoc subgroup analysis with pooled data from two phase II clinical trials. Transl Lung Cancer Res. 2022;11(6):953–63. https://doi.org/10.21037/TLCR-21-995/COIF) .
doi: 10.21037/TLCR-21-995/COIF)
pubmed: 35832438
pmcid: 9271433
Svaton M, Pesek M, Chudacek Z, Vosmiková H. Current two EGFR mutations in lung adenocarcinoma—case report. Klin Onkol. 2015;28(2):134–7. https://doi.org/10.14735/AMKO2015134 .
doi: 10.14735/AMKO2015134
pubmed: 25882025
Watanabe M, Oizumi S, Kiuchi S, et al. The effectiveness of afatinib in a patient with advanced lung adenocarcinoma harboring rare G719X and S768I mutations. Intern Med. 2018;57(7):993–6. https://doi.org/10.2169/INTERNALMEDICINE.9565-17 .
doi: 10.2169/INTERNALMEDICINE.9565-17
pubmed: 29225262
Yang Y, Zhang B, Li R, Liu B, Wang L. EGFR-tyrosine kinase inhibitor treatment in a patient with advanced non-small cell lung cancer and concurrent exon 19 and 21 EGFR mutations: a case report and review of the literature. Oncol Lett. 2016;11(5):3546–50. https://doi.org/10.3892/ol.2016.4409 .
doi: 10.3892/ol.2016.4409
pubmed: 27123149
pmcid: 4841118
Morimoto T, Yamasaki K, Shingu T, et al. A rare case of double primary lung adenocarcinomas with uncommon complex EGFR G719X and S768I mutations and pleomorphic carcinoma. Thorac Cancer. 2023;14(29):2981–4. https://doi.org/10.1111/1759-7714.15085 .
doi: 10.1111/1759-7714.15085
pubmed: 37614204
pmcid: 10569900
Simionato F, Calvetti L, Cosci M, Scarparo S, Aprile G. Case report: a metabolic complete response to upfront osimertinib in a smoker non-small cell lung cancer patient harbouring EGFR G719A/V769M complex mutation. Oncol Targets Ther. 2020;13:12027–31. https://doi.org/10.2147/OTT.S280933 .
doi: 10.2147/OTT.S280933
Falla-Martinez JC, Espinosa D, Baena JC, Rodriguez LX, Sua LF, Zambrano AR. An endothelial growth factor receptor compound mutation of T790M substitution with exon 19 deletion in a previously untreated patient: a case report. J Med Case Rep. 2019;13(1):1–8. https://doi.org/10.1186/S13256-019-2075-Y/TABLES/1 .
doi: 10.1186/S13256-019-2075-Y/TABLES/1
He S-Y, Lin Q-F, Chen J, Yu G-P, Zhang J-L, Shen D. Efficacy of afatinib in a patient with rare EGFR (G724S/R776H) mutations and amplification in lung adenocarcinoma: a case report. World J Clin cases. 2021;9(6):1329–35. https://doi.org/10.12998/wjcc.v9.i6.1329 .
doi: 10.12998/wjcc.v9.i6.1329
pubmed: 33644199
pmcid: 7896682
Qin BD, Jiao XD, Yuan LY, et al. The effectiveness of afatinib and osimertinib in a Chinese patient with advanced lung adenocarcinoma harboring a rare triple EGFR mutation (R670W/H835L/L833V): a case report and literature review. Oncol Targets Ther. 2018;11:4739–45. https://doi.org/10.2147/OTT.S167346 .
doi: 10.2147/OTT.S167346
Yang M, Tong X, Xu X, et al. Case report: osimertinib achieved remarkable and sustained disease control in an advanced non-small-cell lung cancer harboring EGFR H773L/V774M mutation complex. Lung Cancer. 2018;121:1–4. https://doi.org/10.1016/j.lungcan.2018.04.006 .
doi: 10.1016/j.lungcan.2018.04.006
pubmed: 29858019
Li L, Huang S, Qin L, Yan N, Shen S, Li X. Successful treatment of lung adenocarcinoma complicated with a rare compound EGFR mutation L833V/H835L using aumolertinib: a case report and literature review. Front Pharmacol. 2023;14:1257592. https://doi.org/10.3389/FPHAR.2023.1257592/BIBTEX .
doi: 10.3389/FPHAR.2023.1257592/BIBTEX
pubmed: 37719840
pmcid: 10499621